Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 3,782 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ARMS Clear all
Completed Not applicable Interventional Results available

Rapid Radiation Therapy for Painful Osseous Metastatic Disease

NCT01391234
View directory record Official record
Conditions
Bone Metastases
Interventions
STAT RT planning and delivery workflow
Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Clinical Impact of L-PRF, H-PRF or the Use of Surgical Stent on Palatal Donor Site Healing.

NCT04758702
View directory record Official record
Conditions
Lack of Keratinized Gingiva
Interventions
L-PRF (Leucocyte- platelet rich fibrin), H-PRF (Horizontal -platelet rich fibrin), Surgical stent
Biological · Device
Lead sponsor
Abdo Y Ismail
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting Phase 4 Interventional

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

NCT07609940
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions
Linvoseltamab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Los Angeles, California • St. Petersburg, Florida • Baton Rouge, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Salvage Peanut Oral Immunotherapy Study

NCT03251508
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02823574
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Nivolumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
28
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

NCT02005666
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo
Drug
Lead sponsor
Zydus Lifesciences Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

NCT03587805
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
1,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
95
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting No phase listed Observational

Mako-MORE Registry

NCT07647354
View directory record Official record
Conditions
Arthropathy of Knee, Arthropathy of Hip
Interventions
Mako Robotic-Arm Assisted Arthroplasty
Device
Lead sponsor
Stryker Orthopaedics
Industry
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
5
States / cities
Jacksonville, Florida • Louisville, Kentucky • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

Post Market Study of Parietene™ DS Composite Mesh in Ventral Hernia Repair

NCT03495154
View directory record Official record
Conditions
Ventral Hernia
Interventions
Parietene DS Composite Mesh
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Baton Rouge, Louisiana • Columbia, Missouri • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

NCT03634241
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
Interventions
Pembrolizumab, Quality-of-Life Assessment, Computed Tomography, Biospecimen Collection
Biological · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer

NCT00051480
View directory record Official record
Conditions
Esophageal Cancer
Interventions
TNFerade
Genetic
Lead sponsor
GenVec
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

NCT07310420
View directory record Official record
Conditions
Advanced Breast Cancer, Early Breast Cancer
Interventions
ZOLADEX
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Hot Springs, Arkansas • Washington D.C., District of Columbia • Ocoee, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

NCT04051996
View directory record Official record
Conditions
ACUTE MYELOID LEUKEMIA
Interventions
Glasdegib, Decitabine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

NCT04388527
View directory record Official record
Conditions
Covid-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke

NCT03985761
View directory record Official record
Conditions
Stroke
Interventions
Home Telerehabilitation using HoVRS
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
40 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

NuroSleeve Powered Brace & Stimulation System to Restore Arm Function

NCT04798378
View directory record Official record
Conditions
Neurologic Diseases, Hemiparesis, Quadriplegia, Muscular Dystrophies, Arthrogryposis, Spinal Cord Injuries, Charcot-Marie-Tooth, Stroke, Weakness of Extremities as Sequela of Stroke, Weakness Due to Upper Motor Neuron Dysfunction, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Arm Paralysis, Cerebral Palsy
Interventions
Neurosleeve
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Wilmington, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

NCT07030868
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes
Interventions
LY3549492, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
38
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Greenbrae, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Use of Digital Tomosynthesis for Detection and Case Management of Scaphoid and Distal Radius Fractures: A VolumeRAD Data Collection Study

NCT03856450
View directory record Official record
Conditions
Distal Radius Fracture, Scaphoid Fracture
Interventions
DTS, X-ray, MRI or CT
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

NCT02269943
View directory record Official record
Conditions
Nasopharyngeal Neoplasms
Interventions
CC-486
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

NCT05082974
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Vance Thompson Vision ND
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Proximal Strengthening for the Management of Wrist Pain

NCT02435979
View directory record Official record
Conditions
Wrist Injuries
Interventions
hand therapy, Proximal Strengthening
Other
Lead sponsor
Mitchell Selhorst
Other
Eligibility
8 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Columbus, Ohio • Dublin, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

NCT07729462
View directory record Official record
Conditions
Preventive Treatment of Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
19
States / cities
Scottsdale, Arizona • Canoga Park, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting Phase 4 Interventional

Tirbanibulin for Pediatric Warts

NCT06791525
View directory record Official record
Conditions
Warts Hand
Interventions
Tirbanibulin ointment 1%
Drug
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
8 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

NCT04398368
View directory record Official record
Conditions
Stage 0a Renal Pelvis and Ureter Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8, Stage 0a Ureter Cancer AJCC v8, Stage 0is Renal Pelvis and Ureter Cancer AJCC v8, Stage 0is Renal Pelvis Cancer AJCC v8, Stage 0is Ureter Cancer AJCC v8, Stage I Renal Pelvis and Ureter Cancer AJCC v8, Stage I Renal Pelvis Cancer AJCC v8, Stage I Ureter Cancer AJCC v8, Stage II Renal Pelvis and Ureter Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8
Interventions
Gemcitabine Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 22, 2026, 4:13 PM EDT